Biofargo News & Blog

I. Why “Anti-VEGF + Anti-Inflammation” Dual-Target Research Is Gaining Momentum Again In the field of neovascular age-related macular degeneration (nAMD), anti-VEGF-based strategies have reshaped vision science over the past decade. However, recent...

I. An Old Challenge in Cardiovascular Gene Delivery Research Comes Back Into Focus Dilated cardiomyopathy (DCM) has long been a recurring but progress-limited topic in cardiovascular basic research. Left ventricular dilation and...

I. Why Anti-AAV Immunoassays Are Becoming Increasingly Critical in AAV Vector Research One of the most challenging aspects of working with adeno-associated virus (AAV) vectors is the presence of pre-existing anti-AAV antibodies in human...

Erythropoietin (EPO) is far more than a hematology reagent. Beyond its well-known role in driving red blood cell production, EPO is a versatile signaling molecule with applications spanning hypoxia biology, neuroscience, cardiovascular...

You’ve decided to add recombinant human Erythropoietin (rhEPO) to your reagent shelf. Maybe you’re starting an erythroid differentiation project, validating a new HIF-pathway inhibitor, or running TF-1 cell bioassays. Either way, not...

Notes from SAPA-NC 2026 — Beyond Borders, Beyond Biotech Frontiers Last week at the SAPA-NC Biotech Innovation & Investment Summit in Research Triangle Park, one of the most thought-provoking talks centered on...